Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Prof Anant Mohan, Tejas Pawan Tiwari, Tejas Menon Suri, Saurabh Mittal, Ankit Patel, Ujjalkumar Avinash Jain, Thirumurthy Velpandian, Ujjalkumar Subhash Das, Tarun Krishna Boppana, Sushil Ravindra Mohan Pandey, Sushil Suresh Shelke, Angel Rajan Singh, Sushma Bhatnagar, Shet Masih, Shelly Mahajan, Tanima Dwivedi, Biswajeet Sahoo, Anuja Pandit, Shweta Bhopale, Saurabh Vig, Ritu Gupta, Karan Madan, Vijay Hadda, Nishkarsh Gupta, Rakesh Garg, Ved Prakash Meena, Randeep Guleria
Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CONFLICTS OF INTEREST: None to declare
References
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis IJID Off Publ Int Soc Infect Dis
Borghesi, Maroldi, COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression, Radiol Med
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Chaccour, Casellas, Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
Changeux, Amoura, Rey, Miyara, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, C R Biol
Chiu, Taub, Sestokas, Lu, Jacob, Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat, Drug Metab Rev
De, Cg, Gregianin, Burger, Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection, Leuk Lymphoma
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Guzzo, Furtek, Porras, Chen, Tipping et al., Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects, Pharmacokinet Pharmacodyn
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot
J O U R N A L P R E, -p r o o f
Krause, Buisson, Bertrand, Corringer, Galzi et al., Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor, Mol Pharmacol
Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol
Lifschitz, Virkel, Sallovitz, Sutra, Galtier et al., Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle, Vet Parasitol
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA
Mastrangelo, Pezzullo, Burghgraeve, Kaptein, Pastorino et al., Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother
Omura, Crump, Ivermectin: panacea for resource-poor communities?, Trends Parasitol
Peña-Silva, Duffull, Steer, Jaramillo-Rincon, Gwee et al., Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19, Br J Clin Pharmacol
Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC J Med Sci
Rahman, Iqbal, Islam, Niaz, Hussain et al., Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients, J Bangladesh Coll Physicians Surg
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease, Chest
Rao, Manissero, Steele, Pareja, A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19, Infect Dis Ther
Samaha, Mouawia, Fawaz, Hassan, Salami et al., Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon, Viruses
Shu, Onwujekwe, Okonkwo, Do alcoholic beverages enhance availability of ivermectin?, Eur J Clin Pharmacol
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Wolff, Nee, Hickey, Marschollek, Risk factors for Covid-19 severity and fatality: a structured literature review, Infection
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T02:13:59Z', 'timestamp': 1712542439062},
'reference-count': 28,
'publisher': 'Elsevier BV',
'issue': '12',
'license': [ { 'start': { 'date-parts': [[2021, 12, 1]],
'date-time': '2021-12-01T00:00:00Z',
'timestamp': 1638316800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}],
'funder': [ { 'DOI': '10.13039/501100001843',
'name': 'Science and Engineering Research Board',
'doi-asserted-by': 'publisher',
'award': ['CVD/2020/001105']},
{ 'DOI': '10.13039/501100006143',
'name': 'Department of Science and Technology, Government of Kerala',
'doi-asserted-by': 'publisher'},
{ 'DOI': '10.13039/501100001409',
'name': 'Department of Science and Technology, Ministry of Science and Technology, India',
'doi-asserted-by': 'publisher'}],
'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'jiac-j.com', 'clinicalkey.es',
'clinicalkey.fr', 'clinicalkey.com.au', 'elsevier.com',
'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2021, 12]]},
'DOI': '10.1016/j.jiac.2021.08.021',
'type': 'journal-article',
'created': {'date-parts': [[2021, 8, 25]], 'date-time': '2021-08-25T05:04:47Z', 'timestamp': 1629867887000},
'page': '1743-1749',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 28,
'title': 'Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre '
'randomized, placebo-controlled trial',
'prefix': '10.1016',
'volume': '27',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2383-9437',
'authenticated-orcid': False,
'given': 'Anant',
'family': 'Mohan',
'sequence': 'first',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-5136-4221',
'authenticated-orcid': False,
'given': 'Pawan',
'family': 'Tiwari',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-2010-4651',
'authenticated-orcid': False,
'given': 'Tejas Menon',
'family': 'Suri',
'sequence': 'additional',
'affiliation': []},
{'given': 'Saurabh', 'family': 'Mittal', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ankit', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []},
{'given': 'Avinash', 'family': 'Jain', 'sequence': 'additional', 'affiliation': []},
{'given': 'Thirumurthy', 'family': 'Velpandian', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-3749-4975',
'authenticated-orcid': False,
'given': 'Ujjalkumar Subhash',
'family': 'Das',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-9970-3712',
'authenticated-orcid': False,
'given': 'Tarun Krishna',
'family': 'Boppana',
'sequence': 'additional',
'affiliation': []},
{'given': 'Ravindra Mohan', 'family': 'Pandey', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sushil Suresh', 'family': 'Shelke', 'sequence': 'additional', 'affiliation': []},
{'given': 'Angel Rajan', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sushma', 'family': 'Bhatnagar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Shet', 'family': 'Masih', 'sequence': 'additional', 'affiliation': []},
{'given': 'Shelly', 'family': 'Mahajan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tanima', 'family': 'Dwivedi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Biswajeet', 'family': 'Sahoo', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-4609-903X',
'authenticated-orcid': False,
'given': 'Anuja',
'family': 'Pandit',
'sequence': 'additional',
'affiliation': []},
{'given': 'Shweta', 'family': 'Bhopale', 'sequence': 'additional', 'affiliation': []},
{'given': 'Saurabh', 'family': 'Vig', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-5364-4086',
'authenticated-orcid': False,
'given': 'Ritu',
'family': 'Gupta',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-5330-6391',
'authenticated-orcid': False,
'given': 'Karan',
'family': 'Madan',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-5820-3685',
'authenticated-orcid': False,
'given': 'Vijay',
'family': 'Hadda',
'sequence': 'additional',
'affiliation': []},
{'given': 'Nishkarsh', 'family': 'Gupta', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rakesh', 'family': 'Garg', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ved Prakash', 'family': 'Meena', 'sequence': 'additional', 'affiliation': []},
{'given': 'Randeep', 'family': 'Guleria', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'issue': '5',
'key': '10.1016/j.jiac.2021.08.021_bib1',
'doi-asserted-by': 'crossref',
'first-page': '533',
'DOI': '10.1016/S1473-3099(20)30120-1',
'article-title': 'An interactive web-based dashboard to track COVID-19 in real time',
'volume': '20',
'author': 'Dong',
'year': '2020',
'journal-title': 'Lancet Infect Dis'},
{ 'issue': '9',
'key': '10.1016/j.jiac.2021.08.021_bib2',
'doi-asserted-by': 'crossref',
'first-page': '445',
'DOI': '10.1016/j.pt.2014.07.005',
'article-title': 'Ivermectin: panacea for resource-poor communities?',
'volume': '30',
'author': 'Omura',
'year': '2014',
'journal-title': 'Trends Parasitol'},
{ 'issue': '3',
'key': '10.1016/j.jiac.2021.08.021_bib3',
'doi-asserted-by': 'crossref',
'first-page': '851',
'DOI': '10.1042/BJ20120150',
'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear '
'import able to inhibit replication of HIV-1 and dengue virus',
'volume': '443',
'author': 'Wagstaff',
'year': '2012',
'journal-title': 'Biochem J'},
{ 'issue': '8',
'key': '10.1016/j.jiac.2021.08.021_bib4',
'doi-asserted-by': 'crossref',
'first-page': '1884',
'DOI': '10.1093/jac/dks147',
'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically '
'targeting NS3 helicase activity: new prospects for an old drug',
'volume': '67',
'author': 'Mastrangelo',
'year': '2012',
'journal-title': 'J Antimicrob Chemother'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib5',
'doi-asserted-by': 'crossref',
'first-page': '104760',
'DOI': '10.1016/j.antiviral.2020.104760',
'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear '
'transport importin α/β1 heterodimer',
'volume': '177',
'author': 'Yang',
'year': '2020',
'journal-title': 'Antivir Res'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib6',
'doi-asserted-by': 'crossref',
'first-page': '104787',
'DOI': '10.1016/j.antiviral.2020.104787',
'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 '
'in vitro',
'volume': '178',
'author': 'Caly',
'year': '2020',
'journal-title': 'Antivir Res'},
{ 'issue': '2–3',
'key': '10.1016/j.jiac.2021.08.021_bib7',
'doi-asserted-by': 'crossref',
'first-page': '289',
'DOI': '10.3109/03602538708998309',
'article-title': 'Comparative in vivo and in vitro metabolism of ivermectin in steers, '
'sheep, swine, and rat',
'volume': '18',
'author': 'Chiu',
'year': '1987',
'journal-title': 'Drug Metab Rev'},
{ 'issue': '4',
'key': '10.1016/j.jiac.2021.08.021_bib8',
'doi-asserted-by': 'crossref',
'first-page': '327',
'DOI': '10.1016/S0304-4017(99)00175-2',
'article-title': 'Comparative distribution of ivermectin and doramectin to parasite '
'location tissues in cattle',
'volume': '87',
'author': 'Lifschitz',
'year': '2000',
'journal-title': 'Vet Parasitol'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib9',
'first-page': '214',
'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may '
'reduce the duration of illness',
'volume': '103',
'author': 'Ahmed',
'year': '2021',
'journal-title': 'Int J Infect Dis IJID Off Publ Int Soc Infect Dis'},
{ 'issue': '6',
'key': '10.1016/j.jiac.2021.08.021_bib10',
'doi-asserted-by': 'crossref',
'first-page': '989',
'DOI': '10.3390/v13060989',
'article-title': 'Effects of a single dose of ivermectin on viral and clinical outcomes '
'in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in '
'Lebanon',
'volume': '13',
'author': 'Samaha',
'year': '2021',
'journal-title': 'Viruses'},
{ 'issue': '14',
'key': '10.1016/j.jiac.2021.08.021_bib11',
'doi-asserted-by': 'crossref',
'first-page': '1426',
'DOI': '10.1001/jama.2021.3071',
'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults '
'with mild COVID-19: a randomized clinical trial',
'volume': '325',
'author': 'López-Medina',
'year': '2021',
'journal-title': 'J Am Med Assoc'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib12',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.eclinm.2020.100720',
'article-title': 'The effect of early treatment with ivermectin on viral load, symptoms '
'and humoral response in patients with non-severe COVID-19: a pilot, '
'double-blind, placebo-controlled, randomized clinical trial',
'author': 'Chaccour',
'year': '2021',
'journal-title': 'EClinicalMedicine'},
{ 'issue': '10',
'key': '10.1016/j.jiac.2021.08.021_bib13',
'doi-asserted-by': 'crossref',
'first-page': '2536',
'DOI': '10.1080/10428194.2020.1786559',
'article-title': 'Continuous high-dose ivermectin appears to be safe in patients with '
'acute myelogenous leukemia and could inform clinical repurposing for '
'COVID-19 infection',
'volume': '61',
'author': 'de Castro',
'year': '2020',
'journal-title': 'Leuk Lymphoma'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib14',
'unstructured': 'Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et '
'al. Safety, tolerability, and pharmacokinetics of escalating high doses '
'of ivermectin in healthy adult subjects. Pharmacokinet Pharmacodyn. '
':12.'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib15',
'first-page': '1',
'article-title': 'COVID-19 outbreak in Italy: experimental chest X-ray scoring system for '
'quantifying and monitoring disease progression',
'author': 'Borghesi',
'year': '2020',
'journal-title': 'Radiol Med'},
{ 'issue': '3–4',
'key': '10.1016/j.jiac.2021.08.021_bib16',
'doi-asserted-by': 'crossref',
'first-page': '251',
'DOI': '10.1016/j.vetpar.2004.11.028',
'article-title': 'Influence of the route of administration on efficacy and tissue '
'distribution of ivermectin in goat',
'volume': '128',
'author': 'Lespine',
'year': '2005',
'journal-title': 'Vet Parasitol'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib17',
'series-title': 'COVID-19 therapeutic trial synopsis',
'author': 'WHO R&D Blueprint novel Coronavirus',
'year': '2020'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib18',
'first-page': '14476',
'article-title': 'Pharmacokinetic considerations on the repurposing of ivermectin for '
'treatment of COVID‐19',
'author': 'Peña‐Silva',
'year': '2020',
'journal-title': 'Br J Clin Pharmacol'},
{ 'issue': '5',
'key': '10.1016/j.jiac.2021.08.021_bib19',
'doi-asserted-by': 'crossref',
'first-page': '437',
'DOI': '10.1007/s002280000120',
'article-title': 'Do alcoholic beverages enhance availability of ivermectin?',
'volume': '56',
'author': 'Shu',
'year': '2000',
'journal-title': 'Eur J Clin Pharmacol'},
{ 'issue': '2',
'key': '10.1016/j.jiac.2021.08.021_bib20',
'doi-asserted-by': 'crossref',
'first-page': '283',
'DOI': '10.1124/mol.53.2.283',
'article-title': 'Ivermectin: a positive allosteric effector of the alpha7 neuronal '
'nicotinic acetylcholine receptor',
'volume': '53',
'author': 'Krause',
'year': '1998',
'journal-title': 'Mol Pharmacol'},
{ 'issue': '1',
'key': '10.1016/j.jiac.2021.08.021_bib21',
'first-page': '33',
'article-title': 'A nicotinic hypothesis for Covid-19 with preventive and therapeutic '
'implications',
'volume': '343',
'author': 'Changeux',
'year': '2020',
'journal-title': 'C R Biol'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib22',
'first-page': '14',
'article-title': 'Outcome of ivermectin treated mild to moderate COVID-19 cases: a '
'single-centre, open-label, randomised controlled study',
'author': 'Podder',
'year': '2020',
'journal-title': 'IMC J Med Sci'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib23',
'first-page': '1',
'article-title': 'A narrative systematic review of the clinical utility of cycle '
'threshold values in the context of COVID-19',
'author': 'Rao',
'year': '2020',
'journal-title': 'Infect Dis Ther'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib24',
'article-title': 'Use of ivermectin is associated with lower mortality in hospitalized '
'patients with coronavirus disease 2019',
'author': 'Rajter',
'year': '2020',
'journal-title': 'Chest'},
{ 'issue': '9',
'key': '10.1016/j.jiac.2021.08.021_bib25',
'doi-asserted-by': 'crossref',
'first-page': '593',
'DOI': '10.1038/s41429-020-0336-z',
'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 '
'complementary regimen',
'volume': '73',
'author': 'Heidary',
'year': '2020',
'journal-title': 'J Antibiot (Tokyo)'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib26',
'doi-asserted-by': 'crossref',
'first-page': '5',
'DOI': '10.3329/jbcps.v38i0.47514',
'article-title': 'Comparison of viral clearance between ivermectin with doxycycline and '
'hydroxychloroquine with azithromycin in COVID-19 patients',
'author': 'Rahman',
'year': '2020',
'journal-title': 'J Bangladesh Coll Phys Surg'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib27',
'doi-asserted-by': 'crossref',
'first-page': '1054',
'DOI': '10.1016/S0140-6736(20)30566-3',
'article-title': 'Clinical course and risk factors for mortality of adult inpatients with '
'COVID-19 in Wuhan, China: a retrospective cohort study',
'volume': '395',
'author': 'Zhou',
'year': '2020',
'journal-title': 'Lancet'},
{ 'key': '10.1016/j.jiac.2021.08.021_bib28',
'first-page': '1',
'article-title': 'Risk factors for Covid-19 severity and fatality: a structured '
'literature review',
'author': 'Wolff',
'year': '2020',
'journal-title': 'Infection'}],
'container-title': 'Journal of Infection and Chemotherapy',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1341321X21002397?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S1341321X21002397?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2021, 10, 25]],
'date-time': '2021-10-25T17:28:34Z',
'timestamp': 1635182914000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1341321X21002397'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 12]]},
'references-count': 28,
'journal-issue': {'issue': '12', 'published-print': {'date-parts': [[2021, 12]]}},
'alternative-id': ['S1341321X21002397'],
'URL': 'http://dx.doi.org/10.1016/j.jiac.2021.08.021',
'relation': {},
'ISSN': ['1341-321X'],
'subject': ['Infectious Diseases', 'Pharmacology (medical)', 'Microbiology (medical)'],
'container-title-short': 'Journal of Infection and Chemotherapy',
'published': {'date-parts': [[2021, 12]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A '
'single-centre randomized, placebo-controlled trial',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Journal of Infection and Chemotherapy',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.jiac.2021.08.021',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2021 Japanese Society of Chemotherapy and The Japanese Association for '
'Infectious Diseases. Published by Elsevier Ltd. All rights reserved.',
'name': 'copyright',
'label': 'Copyright'}]}
